Previous randomized trials have shown that patients with advanced-stage lung adenocarcinoma and mutations in EGFR, exhibit improved overall response rates, progression-free survival (PFS) (gefitinib: 24.9% vs. carboplatin/paclitaxel: 6.7%; p < 0.001), and quality of life following EGFR-TKI therapy compared to traditional chemotherapy [6,7]. Here, EGFR is linked to lung adenocarcinoma.